Astellas Pharma Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $25.62 billion
- Book Value:
- Revenue TTM:
- $1,468.23 billion
- Operating Margin TTM:
- Gross Profit TTM:
- $1,043.15 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Astellas Pharma Inc had its IPO on under the ticker symbol ALPMF.
The company operates in the Healthcare sector and Drug Manufacturers-General industry. Astellas Pharma Inc has a staff strength of 14,522 employees.
Shares of Astellas Pharma Inc opened at $14.13 at the start of the last trading session i.e. 2023-03-25.
The stocks traded within a range of $14.13 - $14.13, and closed at $14.13.
This is a 0% increase from the previous day's closing price.
A total volume of 0 shares were traded at the close of the day’s session.
In the last one week, shares of Astellas Pharma Inc have increased by +0.78%.
Astellas Pharma Inc's Key Ratios
Astellas Pharma Inc has a market cap of $25.62 billion, indicating a price to book ratio of 2.3776 and a price to sales ratio of 0.0208.
In the last 12-months Astellas Pharma Inc’s revenue was $1,468.23 billion with a gross profit of $1,043.15 billion and an EBITDA of $358.44 billion. The EBITDA ratio measures Astellas Pharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Astellas Pharma Inc’s operating margin was 17.34% while its return on assets stood at 6.53% with a return of equity of 8.98%.
In Q4, Astellas Pharma Inc’s quarterly earnings growth was a negative -20.4% while revenue growth was a positive 18.1%.
Astellas Pharma Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $0.55 per share while it has a forward price to earnings multiple of 15.3139 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Astellas Pharma Inc’s profitability.
Astellas Pharma Inc stock is trading at a EV to sales ratio of 0.0186 and a EV to EBITDA ratio of 0.0883. Its price to sales ratio in the trailing 12-months stood at 0.0208.
Astellas Pharma Inc stock pays annual dividends of $55 per share, indicating a yield of 3.36% and a payout ratio of 0.86%.
Balance sheet and cash flow metrics
- Total Assets
- $2,513.95 billion
- Total Liabilities
- $705.91 billion
- Operating Cash Flow
- Capital Expenditure
- $20.73 billion
- Dividend Payout Ratio
Astellas Pharma Inc ended 2023 with $2,513.95 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2,513.95 billion while shareholder equity stood at $1,570.42 billion.
Astellas Pharma Inc ended 2023 with $0 in deferred long-term liabilities, $705.91 billion in other current liabilities, in common stock, $996.25 billion in retained earnings and $324.07 billion in goodwill. Its cash balance stood at $381.82 billion and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Astellas Pharma Inc’s total current assets stands at $1,072.59 billion while long-term investments were $0 and short-term investments were $31.48 billion. Its net receivables were $451.28 billion compared to accounts payable of $134.24 billion and inventory worth $163.22 billion.
In 2023, Astellas Pharma Inc's operating cash flow was $0 while its capital expenditure stood at $20.73 billion.
Comparatively, Astellas Pharma Inc paid $0.01 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Astellas Pharma Inc stock is currently trading at $14.13 per share. It touched a 52-week high of $16.71 and a 52-week low of $16.71. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $14.41 and 200-day moving average was $14.69 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 37.8% of the company’s stock are held by insiders while 5042.1% are held by institutions.
Frequently Asked Questions About Astellas Pharma Inc
Similar Industry Stocks (Drug Manufacturers-General)
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals in the Japan, United States, and internationally. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of overactive bladder urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.